William Blair initiated coverage of Thermo Fisher (TMO) with an Outperform rating and no price target The firm believes the company’s “one-stop-shop” pharma partnership strategy will drive multiple expansion. It sees share price of $598 at the end of 2026, or 22% upside to current levels. Thermo is partner of choice for the biopharma industry, and while that has constrained shares in the near term, it has (roved to be a resilient and attractive market in the longer term, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher gets FDA approval for Oncomine Dx
- Trinity Biotech announces launch of FDA-cleared preeclampsia testing service
- Thermo Fisher’s Strong Market Position and Growth Drive Buy Rating
- Thermo Fisher’s Strong Performance and Strategic Initiatives Justify Buy Rating Amid Industry Recovery
- Positive Outlook and Strategic Growth Plans Bolster Thermo Fisher’s Stock Rating